NCT05761795
Efficacy of IVMED-85 on Pediatric Myopia
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 2 years 8 months later, primary endpoint(s) modified, and 1 more.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrollment reduced: 216 → 144 participants Show 10 more changesShow less
- Primary endpoint(s) modified
- Primary completion pushed from May 2026 to Feb 2029
- Phase changed: Phase 1/2 → Phase 2
- Start date: Feb 2024 to Feb 2027
- Eligibility criteria shortened, about 76 words
- Study completion pushed from Dec 2026 to Jun 2029
- Interventions modified
- Trial arms changed: 7 → 3
- Secondary endpoints: 6 to 5
- Study description expanded, about 217 words
- Notable Primary completion date: May 2025 to May 2026
- Start date: May 2023 to Feb 2024
- Study completion date: Dec 2025 to Dec 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Refractive error change from baseline at Month 12
Timeframe: Baseline compared to month 12
Secondary (5)
Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
Change in optical biometrics
Refractive error at non-final study visits
Sub foveal choroidal thickness
Accommodative amplitude in the spherical equivalent
Arms and interventions
IVMED-85 Low DoseExperimental
Total subjects n=48, IVMED-85 low dose BID for 12 months
IVMED-85 High DoseExperimental
Total subjects n=48, IVMED-85 high dose BID for 12 months
PlaceboPlacebo comparator
Total subjects n=48, placebo BID for 12 months
Drugs: IVMED-85 ophthalmic solution, Low Dose, IVMED-85 ophthalmic solution, High dose, Placebo